Adaptimmune Therapeutics plc (473A) - Total Liabilities

Latest as of June 2025: €201.59 Million EUR ≈ $235.68 Million USD

Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has total liabilities worth €201.59 Million EUR (≈ $235.68 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 473A asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Adaptimmune Therapeutics plc - Total Liabilities Trend (2016–2024)

This chart illustrates how Adaptimmune Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 473A total asset value.

Adaptimmune Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Adaptimmune Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
OS Therapies Incorporated NYSE MKT:OSTX	USA	$4.25 Million
MeVis Medical Solutions AG XETRA:M3V	Germany	€5.34 Million
GenMont Biotech Inc TW:3164	Taiwan	NT$297.05 Million
Oceanpal Inc NASDAQ:OP	USA	$4.10 Million
Next Bt Co. Ltd KQ:065170	Korea	₩8.41 Billion
Huvis Corporation KO:079980	Korea	₩501.60 Billion
AXIOS Sustainable Growth NYSE:AXAC	USA	$1.18 Million
Sand Nisko Capital Bhd KLSE:7943	Malaysia	RM39.53 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Adaptimmune Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 473A net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.84	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.54	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adaptimmune Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adaptimmune Therapeutics plc (2016–2024)

The table below shows the annual total liabilities of Adaptimmune Therapeutics plc from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€234.11 Million ≈ $273.70 Million	-3.70%
2023-12-31	€243.10 Million ≈ $284.21 Million	-1.59%
2022-12-31	€247.04 Million ≈ $288.81 Million	-6.28%
2021-12-31	€263.58 Million ≈ $308.16 Million	+139.81%
2020-12-31	€109.92 Million ≈ $128.50 Million	+89.82%
2019-12-31	€57.91 Million ≈ $67.70 Million	+93.98%
2018-12-31	€29.85 Million ≈ $34.90 Million	-61.81%
2017-12-31	€78.16 Million ≈ $91.38 Million	+14.32%
2016-12-31	€68.37 Million ≈ $79.94 Million	--

About Adaptimmune Therapeutics plc

F:473A Germany

Market Cap

$50.20 Million

€42.94 Million EUR

Market Cap Rank

#22555 Global

#1980 in Germany

Share Price

€0.16

Change (1 day)

+6.58%

52-Week Range

€0.09 - €0.25

All Time High

€12.93